Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
61 studies found for:    Small Cell Cancer of the Bladder | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Condition: Bladder Cancer
Interventions: Radiation: Prophylactic Cranial Irradiation (PCI);   Other: Brain X-ray
2 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
3 Recruiting A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cobimetinib
4 Not yet recruiting Alisertib in Chemotherapy-pretreated Urothelial Cancer
Conditions: Bladder Cancer;   Transitional Cell Carcinoma
Interventions: Drug: Alisertib;   Drug: Paclitaxel;   Drug: Placebo
5 Recruiting Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Conditions: Acute Myeloid Leukemia;   Brain Glioblastoma;   Estrogen Receptor Negative;   Extensive Stage Small Cell Lung Carcinoma;   Head and Neck Carcinoma;   HER2/Neu Negative;   Hormone-Resistant Prostate Cancer;   Limited Stage Small Cell Lung Carcinoma;   Myelodysplastic Syndrome;   Progesterone Receptor Negative;   Progressive Disease;   Recurrent Carcinoma;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage IIA Pancreatic Cancer;   Stage IIA Rectal Cancer;   Stage IIB Pancreatic Cancer;   Stage IIB Rectal Cancer;   Stage IIC Rectal Cancer;   Stage III Colon Cancer;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Skin Melanoma;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Bladder Cancer;   Stage IV Bone Sarcoma;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IV Soft Tissue Sarcoma;   Stage IVA Bone Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Bone Sarcoma;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Procedure: Supportive Care;   Other: Survey Administration
6 Not yet recruiting A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Urinary Bladder Neoplasms;   Neoplasm Metastasis
Intervention: Drug: Combination of NKTR-214 + atezolizumab
7 Not yet recruiting sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
Conditions: Infiltrating Bladder Urothelial Carcinoma;   Recurrent Bladder Carcinoma;   Stage I Prostate Cancer;   Stage I Renal Cell Cancer;   Stage II Bladder Urothelial Carcinoma;   Stage II Renal Cell Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Procedure: Radical Cystectomy;   Biological: Recombinant EphB4-HSA Fusion Protein;   Procedure: Therapeutic Conventional Surgery
8 Recruiting A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Condition: Neoplasms
Intervention: Drug: JNJ-63723283
9 Recruiting Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Conditions: Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions: Drug: CC-486;   Drug: Vidaza
10 Recruiting Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Conditions: Prostate Cancer;   Bladder Cancer;   Kidney Cancer
Intervention: Drug: Ferumoxytol
11 Not yet recruiting Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
Conditions: Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma;   Stage IV Bladder Urothelial Carcinoma
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Procedure: Radical Cystectomy;   Biological: Tumor Cell-Derived Vaccine Therapy
12 Recruiting Study of Tumour Focused Radiotherapy for Bladder Cancer
Condition: Bladder Cancer
Interventions: Radiation: WBRT;   Radiation: SART;   Radiation: DART
13 Not yet recruiting Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer
Condition: Stage II Bladder Urothelial Carcinoma
Interventions: Procedure: Catheter Management;   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
14 Recruiting Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
Condition: Solid Tumors
Interventions: Drug: NC-6004;   Drug: Gemcitabine
15 Recruiting Tranexamic Acid During Cystectomy Trial (TACT)
Condition: Bladder Cancer
Interventions: Drug: Tranexamic Acid;   Drug: Placebo
16 Recruiting A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Conditions: Urinary Bladder Cancer;   Bladder Tumors;   Transitional Cell Carcinoma of the Bladder;   Malignant Melanoma;   Melanoma;   Skin Cancer;   Carcinoma, Non-Small-Cell Lung;   Lung Cancer
Interventions: Biological: NEO-PV-01;   Biological: Nivolumab;   Other: Adjuvant
17 Recruiting Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Conditions: Recurrent Bladder Urothelial Carcinoma;   Stage 0a Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Cancer With Carcinoma In Situ;   Stage I Bladder Urothelial Carcinoma
Interventions: Drug: Atezolizumab;   Other: Laboratory Biomarker Analysis
18 Recruiting Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma
Condition: Urothelial Bladder Carcinoma
Intervention: Drug: Pembrolizumab (MK-3475)
19 Not yet recruiting Functional Outcomes Following Anal Cancer Treatment
Condition: Anal Cancer
Intervention:
20 Recruiting A Study to Evaluate the Efficacy, and Safety of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer (UBC) or Pancreas/Cholangio Cancer (Kameleon Study)
Condition: Bladder Cancer, Pancreas Cancer, Cholangiocellular Carcinoma
Intervention: Drug: Trastuzumab Emtansine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.